Clinical Trials

Trial Name Description
IND.224 Dr. Scott Ernst
"not yet open" A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases.
Checkmate 218 MEL Dr. S. Ernst
Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Subjects with Unresectable or Metastatic Melanoma
Masterkey 265 MEL Dr. S. Ernst
A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Lahparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c Melanoma
Regeneron BCC Dr. J. Lenehan
A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior H
IND.225 Dr. Scott Ernst
A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
ME.13 MEL Dr. John Lenehan
A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP)
Trilogy MEL Dr. S. Ernst
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Unresectabl

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada